Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Duncavage EJ, et al. Among authors: bejar r. Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853. Blood. 2022. PMID: 36130297 Free PMC article.
The genetic basis of myelodysplastic syndromes.
Bejar R, Ebert BL. Bejar R, et al. Hematol Oncol Clin North Am. 2010 Apr;24(2):295-315. doi: 10.1016/j.hoc.2010.02.001. Hematol Oncol Clin North Am. 2010. PMID: 20359627 Review.
Clinical effect of point mutations in myelodysplastic syndromes.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Bejar R, et al. N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343. N Engl J Med. 2011. PMID: 21714648 Free PMC article.
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.
Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. Murphy DM, et al. Among authors: bejar r. Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27. Leukemia. 2013. PMID: 23708912 Free PMC article. No abstract available.
Toll-like receptor alterations in myelodysplastic syndrome.
Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Wei Y, et al. Among authors: bejar r. Leukemia. 2013 Sep;27(9):1832-40. doi: 10.1038/leu.2013.180. Epub 2013 Jun 14. Leukemia. 2013. PMID: 23765228 Free PMC article.
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. Bejar R, et al. Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15. Blood. 2014. PMID: 25224413 Free PMC article.
147 results